Potential applications of siRNA for pain therapy

Expert Opinion on Biological Therapy

Volumn 4, Issue 4, 2004, Pages 531-542

  Ganju, Pam ^a   Hall, Jonathan ^b  

^a Novartis Inst for Medical Sciences   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic neuropathic pain; Intrathecal application of siRNA; P2X3 receptor; Target validation

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SMALL INTERFERING RNA;

ANALGESIA; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GENE TARGETING; HUMAN; IN VIVO STUDY; KIDNEY DISEASE; NAUSEA; NONHUMAN; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; SEDATION; VOMITING;

ANIMALS; CHRONIC DISEASE; GENE SILENCING; HUMANS; HYPERALGESIA; NEURALGIA; RECEPTORS, PURINERGIC P2; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 1842734241     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.4.531     Document Type: Review

References (57)

1. BIRCH S: The CNS Outlook to 2007, Reuters Business Insight Healthcare. Datamonitor PLC. (2003):1-200.
2. ZIMMERMAN M: Pathobiology of neuropathic pain. Eur. J. Pharm. (2001) 429:23-37.
3. ROWBOTHAM M, HARDEN N, STACEY B et al.: Gabapentin for the treatment of postherpetic neuralgia: a randomised controlled trial. JAMA (1998) 280(21):1837-1842.
4. RICE A, MATON S: Postherpetic neuralgia study group: Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain (2001) 94:215-224.
5. NITU A, WALLIHAN R, SKLJAREVSKI V, RAMADAN N: Emerging trends in the pharmacotherapy of chronic pain. Expert Opin. Investig. Drugs (2003) 12(4):545-559.
6. MCMANUS M, SHARP P: Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. (2002) 3:737-747. A comprehensive review of siRNA.
7. FIRE A, XU S, MONTGOMERY M, KOSTAS S, DRIVER S, MELLO C: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391 (6669):806-811.
8. BERNSTEIN E, CAUDY A, HAMMOND S, HANNON GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference in cultured mammalian cells. Nature (2001) 409(6818):363-366.
9. ELBASHIR S, HARBORTH J, LENDECKEL W et al.: Duplexes of 21-nudeotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
10. STARK G, KERR I, WILLIAMS B et al.: How cells respond to interferons. Annu. Rev. Biochem. (1998) 67:227-264.
11. SCHERER L, ROSSI J: Approaches for the sequence-specific knockdown of mRNA. (2003) Nat. Biotechnol. 21(12):1457-1465. An informative review comparing ASOs, ribozymes, DNAzymes and RNAi approaches for mRNA knockdowns.
12. MAKIMURA H, MIZUNO TM, MASTAITLIS JW, AGAMI R, MOBBS CV: Reducing hypothalmic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neuroscience (2003) 3:18.
13. SONG E, LEE S, WANG J et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. (2003) 9(3):347-351.
14. VERMA U, SURABHI R, SCHMALTIEG A. et al.: Small interfering RNAs directed against β-catanin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. (2003) 9(4):1291-1300.
15. SORENSEN D, LEIRDAL M, SIOUD M: Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. (2003) 327(4):761-766. Recognises that different siRNAs demonstrate various levels of potency and require characterisation before initiation of in vivo studies, that reagent delivery to target tissue may require specialist reagents, although the use of liposomes may not be permitted in man, and the use of siRNAs to inhibit a protein with a known role in several disease indications.
16. FILLEUR S, COURTIN A, AIT-SI-ALI S et al.: siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularisation and growth. Cancer Res. (2003) 63:3919-3922.
17. REICH S, FOSNOT J, KUROKI A et al.: small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularisation in a mouse model. Mol. Vis. (2003) 9:210-216.
18. ZENDER L, HUTKER S, LIEDTKE C et al.: Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. USA (2003) 100(13):7797-7802.
19. DORN G, PATEL S, WOTHERSPOON G et al.: RNA interference blocks chronic pain in vivo. Br. Neurosci. Assoc. Abstr. (2003) 17:P63.09. The first demonstration of the utility of siRNA in chronic pain.
20. DORN G, PATEL S, WOTHERSPOON G et al.: RNA interference blocks chronic pain in vivo. (2004) (In press).
21. BARCLAY J, PATEL S, DORN G et al.: Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain. J. Neurosci. (2002) 22:8139-8147.
22. HONORE P, KAGE K, MIKUSA J et al.: Analgesic profile of intrathecal P2X3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain (2002) 99:11-19.
23. COCKAYNE D, HAMILTON S, ZHU Q et al.: Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature (2000) 407:1011-1015.
24. SOUSLOVA V, CESARE P, DING Y et al.: Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature (2000) 407:1015-1017.
25. JARVIS M, BURGARD E, MCGARAUGHTY S et al.: A-317491, a novel potent and selective nonnucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc. Natl. Acad. Sci. USA (2002) 99(26):17179-17184.
26. MCGARAUGHTY S, WISMER C, ZHU C et al.: Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration. Br. J. Pharmacol. (2003) 140:1381-1388.
27. LAVERY K, KING T: Antisense and RNA1: powerful tools in drug discovery and validation. Curr. Opin. Drug Discov. (2003) 6(4):561-569.
28. MANTYH P, CLOHISY D, KOLTZENBURG M et al.: Molecular mechanisms of cancer pain. Nat. Rev. (2002) 20:201-209.
29. CRAIG A: Pain mechanisms: labelled lines versus convergence in central processing. Ann. Rev. Neurosci. (2003) 26:1-30.
30. SELTZER Z, DUBNER R, SHIR Y: A novel behavioural model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain (1990) 43:205-218.
31. LAI J, PORRECA F, HUNTER J et al.: Voltage-gated sodium channel and hyperalgesia. Ann. Rev. Pharmacol. Toxicol. (2004) 44:371-397.
32. v1.8. Pain (2002) 95:143-152. Demonstrates that antisense-mediated knockdown of this channel reverses signs of abnormal pain in a model of chronic pain, suggesting it could be a key target for intervention in pain.
33. v1.8 in uninjured axons enables neuropathic pain. J. Neurosci. (2003) 23:153-186.
34. PORECCA F, LAI J, BIAN D et al.: A comparison of the potential role of the terrodotoyin-insensitive sodium channels, PN3/and NaN/SNS2, in rat models of chronic pain. Proc. Natl. Acad. Sci. USA (1999) 99:7640-7644.
35. AUGUSTINE G, CHARLTON M, SMITH S: Calcium action in synaptic transmitter release. Ann. Rev. Neurosci. (1987) 10:633-693.
36. HEADING C: Ziconotide. Curr. Opin. CPNS Investig. Drugs (1999) 1:153-166.
37. AL-GHOUL W, LI VOLSI G, WEINBERG R et al.: Glutamate immunocytochemistry in the dorsal horn after injury or stimulation of the sciatic nerves of rats. Brain Res. Bull. (1993) 340:453-459.
38. FUNDYTUS M, YASHPAL K, CHABOT J-C et al.: Knockdown of spinal metabotropic glutamate receptor 1 (mGluR1) alleviates pain and restores opioid efficacy after nerve injury in rats. Br. J. Pharm. (2001) 132:354-367.
39. v1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J. Neurosci. (2003) 23(26):8881-8892.
40. NELSON P, SOMA L, LAVI E: Microglia in diseases of the central nervous system. Ann. Med. (2002) 34(7-8):491-500.
41. TSUDA M, SHIGEMOTO-MOGAMI Y, KOIZUMI S: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature (2003) 424:778-783. This study demonstrates that microglial genes are amenable to antisense knockdown and could be potential targets for chronic pain intervention.
42. KEST B, HOPKINS E, PALMESE C et al.: Genetic variation in morphine analgesic tolerance: a survey of 11 inbred mouse strains.(2002) Pharmacol. Biochem. Behav 73(4):821-828.
43. PRZEWLOCKA B, SIEJA A, STAROWICZ K et al.: Knockdown of spinal opioid receptors by antisense targeting β-arrest in reduces morphine tolerance and allodynia in rat. Neurosci. Lett. (2002) 325:107-110.
44. FERGUSON S, DOWNEY W III, COLAPIETRO A et al.: Role of β-arrestin in mediation agonist-promoted G protein-coupled receptor internalisation. Science (1996) 271:363-366.
45. WU C, GARRY M, ZOLLO R et al.: Gene therapy for the management of pain. Anesthesiol. (2001) 94:1119-1131.
46. MCCAFFERY A, MEUSE L, PHAM T et al.: RNA interference in adult mice. Nature (2002) 418(6893):38-39.
47. LEWIS D, HAGSTROM J, LOOMIS A et al.: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice (2002) Nat. Genet 32(1):107-108. Shows that synthetic, duplexed oligoribonucleotides bearing no modifications are sufficiently stable in mice for some applications through intravenous injection and that a small but relevant set of body organs can be reached without the need for complex formulations.
48. BARDON A, SIERAKOWSKA H, SHUGAR D: Human pancreatic-type ribonucleases with activity against double-stranded ribonucleic acids. Biochim. Biophys. Acta (1976) 438(2):461-473.
49. ELBASHIR S, HARBORTH J, WEBER K et al.: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods (2002) 26:199-213.
50. REYNOLDS A, LEAKE D, BOESE Q, et al.: Rational siRNA design for RNA interference. Nat. Biotechnol. (2004) (In Press) [Epub ahead of print]. Describes features associated with siRNA functionality: low G/C content, a bias towards low internal stability at the sense strand 3′-terminus, lack of inverted repeats, and sense strand base preferences.
51. FREIER S, KIERZEK R, JAEGER Jet al.: Improved free-energy parameters for predictions of RNA duplex stability. Proc. Natl. Acad. Sci. USA (1986) 83(24):9373-9377.
52. CHI J, CHANG H, WANG N et al.: Genomewide view of gene silencing by small interfering RNAS. Proc. Natl. Acad. Sci. USA (2003) 100(11):6343-6346. This study explores the selectivity of RNAi.
53. SEMIZAROV D, FROST L, SARTHY A et al.: Specificity of short interfering RNA determined through gene expression signatures. (2003) Proc. Natl. Acad. Sci. USA 100(11):6347-6352. This study explores the selectivity of RNAi.
54. JACKSON A, BARTZ S, SCHELTER J et al.: Expression profiling reveals off-target regulation by RNAi. Nat. Biotechnol. (2003) 21(6):635-638. This study explores the off-target effects of RNAi.
55. KISIELOW M, KLEINER S, NAGASAWA M, FAISAL A, NAGAMINE M: Isoform-specific knockdown and expression of adaptor protein shc A using small interfering RNA. Biochem. J. (2002) 363(1):1-5.
56. SLEDZ C, HOLKO M, DE VEER M et al.: Activation of the interferon system by short-interfering RNAs. (2003) Nat. Cell Biol. 5(9):834-839.
57. BRIDGE A, PEBERNARD S, DUCRAUX A et al.: Induction of an interferon response by RNAi vectors in mammalian cells. (2003) Nat. Genet. 34(3):263-264.